CytoMed Therapeutics Limited

Company info

Countries of Operation

Singapore

Founding Year

2018

Number of Employees

6–10

Company overview

Full Description

Incorporated in 2018, CytoMed is a biotech company spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector, and focused on translating its proprietary technologies into cell-based immunotherapy cancer treatments. The development of these novel technologies was inspired by the clinical success of chimeric antigen receptor-modified T (CAR-T) cells in treating hematological malignancies and introduces solutions for the clinical limitations and commercial challenges inherent in extrapolating the CAR-T principle into treatments for solid tumors.

Areas of focus

Cellular Immunotherapy

Problem Statement

The development of CD19-targeting CAR-T cells to treat B-cell malignancies underscores cellular immunotherapy’s increasingly essential role in cancer care. However, the therapies in use today face several challenges that include: reliance on a patient’s limited cell quality and quantity, the lack of “safe” surface cancer antigens and their recognition system, and the limited success rate of relying on a single antigen-targeting strategy. Applying the current CAR-T principle when treating other types of cancers, particularly solid tumors, can be challenging.

Product & IP